Instances of early (<30 days post-PEX) termination of caplacizumab treatment stratified according to outcome (ie, nonsuccessful [exacerbation, relapse, or death] vs successful [no such event])
| Approach . | Successful . | Nonsuccessful . |
|---|---|---|
| ADAMTS13 guided | 15 | 0 |
| Platelet count guided | 11 | 9 |
| Total | 26 | 9 |
| Approach . | Successful . | Nonsuccessful . |
|---|---|---|
| ADAMTS13 guided | 15 | 0 |
| Platelet count guided | 11 | 9 |
| Total | 26 | 9 |
An ADAMTS13-guided approach was assumed when a (rising) ADAMTS13 activity >10% was known to the treating physicians at the time of stopping caplacizumab. A platelet count–guided approach was assumed when no such activity measurement was known or activity was still <10% at the time of stopping caplacizumab.